Ultra-low-dose in brain 18F-FDG PET/MRI in clinical settings

Marine Soret1,2,*, Jacques-Antoine Maisonobe1,2, Serge Desarnaud1, Sébastien Bergeret1, Valérie Cause-Lemercier1, Arnaud Berenbaum1, Laura Rozenblum1, Marie-Odile Habert1,2,3 & Aurélie Kas1,2

We previously showed that the injected activity could be reduced to 1 MBq/kg without significantly degrading image quality for the exploration of neurocognitive disorders in 18F-FDG-PET/MRI. We now hypothesized that injected activity could be reduced ten-fold. We simulated a 18F-FDG-PET/MRI ultra-low-dose protocol (0.2 MBq/Kg, PETULD) and compared it to our reference protocol (2 MBq/Kg, PETSTD) in 50 patients with cognitive impairment. We tested the reproducibility between PETULD and PETSTD using SUVratios measurements. We also assessed the impact of PETULD for between-group comparisons and for visual analysis performed by three physicians. The intra-operator agreement between visual assessment of PETSTD and PETULD in patients with severe anomalies was substantial to almost perfect (kappa > 0.79). For patients with normal metabolism or moderate hypometabolism however, it was only moderate to substantial (kappa > 0.53). SUV ratios were strongly reproducible (SUVratio difference ± SD = 0.09 ± 0.08). Between-group comparisons yielded very similar results using either PETULD or PETSTD. 18F-FDG activity may be reduced to 0.2 MBq/Kg without compromising quantitative measurements. The visual interpretation was reproducible between ultra-low-dose and standard protocol for patients with severe hypometabolism, but less so for those with moderate hypometabolism. These results suggest that a low-dose protocol (1 MBq/Kg) should be preferred in the context of neurodegenerative disease diagnosis.

Abbreviations

PETULD  Positron emission tomography with ultra-low dose activity
PETSTD  Positron emission tomography with standard activity
SUVR  Cortex-to-pons uptake ratios
SUVRSTD  Cortex-to-pons uptake ratios for PETSTD
SUVRULD  Cortex-to-pons uptake ratios for PETULD
N  Normal
NE  Non-evaluable
AD  Alzheimer’s disease
lvPPA  Logogenic variant of progressive primary aphasia
PCA  Posterior cortical atrophy
svPPA  Semantic variant of progressive primary aphasia
FTD  Frontotemporal dementia
CI  Confidence intervals
Ant.  Anterior
Post.  Posterior
Sup.  Superior
Inf.  Inferior

In the last five years, PET technology has improved significantly with the development of new silicon-based detector technology, combined with an increased axial field of views resulting overall in higher sensitivity of modern PET cameras. For brain 18F-FDG PET/MRI, total acquisition time reduction is limited by MR, which usually lasts 20 min or more. Hence, further 18F-FDG radiotracer dose reduction may be achieved by increasing the PET acquisition duration to match that of MR1. We previously showed in 100 patients with suspected neurodegenerative dementia that the injected activity of 18F-FDG could be reduced by half without qualitatively...
or quantitatively degrading 18F-FDG PET/MR image quality. Other studies have used sophisticated deep learning approaches to produce high-quality PET images from low-dose PET acquisitions, or to denoise low-dose PET acquisitions. These methods enable a substantial dose reduction without noise increase or loss in image quality, but have mostly been explored in research applications and have yet to become widely accessible in the clinical setting.

In the present study, we sought to assess whether the injected activity of 18F-FDG could be further decreased in the clinical setting to as low as ten-fold less than current recommendations for brain imaging, by reducing scanning time in clinical settings. We also evaluated the reliability of images resulting from this ultra-low-dose 18F-FDG PET/MR protocol in two patient groups with suspected neurodegenerative dementia, the first with normal metabolism or moderately decreased metabolism, and the second with severe hypometabolism.

Material and methods

We retrospectively simulated the stepwise reduction of 18F-FDG injected activity in 50 patients (67.4 ± 7.2 years old, 26 men) who underwent 18F-FDG PET on a SIGNA 3 T PET/MR system (GE Healthcare) for cognitive impairment or suspected neurodegenerative dementia. These patients had an average weight of 70 ± 11 kg and pre-scan glucose level ranging from 5 to 8 mmol/L.

The raw data were extracted from a previously described cohort of patients belonging to the Pitié-Salpêtrière Hospital database. This database was approved by the French authority for the protection of privacy and personal data in clinical research (CNIL, approval No. 2111722). The use of patient data was performed in accordance with French regulations on bioethics and medical research. In France, according to the law “loi Jardé” (article L. 1121-1 of the public health code) governing scientific research on human subjects, patient data can be used for retrospective scientific research without the prior approval of an ethical committee. All subjects had given their consent for the use of their data for research purposes. We performed this study in accordance with the principles of the Declaration of Helsinki.

Following the revised EANM guidelines for 18F-FDG brain PET, all scans were performed in standardized resting (reduced ambient noise, from 10 min before injection to 25 min post injection) and euglycemic conditions (at least 4 h of fasting). A 18F-FDG activity of 2 MBq/Kg was injected 31 ± 5 min prior to a 30 min brain PET/MRI including MRI sequences and a 20-min single-bed-position PET acquisition acquired simultaneously (i.e. during 18F-FDG equilibrium). 18F-FDG syringes were prepared by a Unidose automatic radiopharmaceutical dispenser (Trasis, Belgium), ranging from 125 to 250 MBq. The average injected activity per subject was 140 ± 17 MBq (between 110 and 201 MBq). PET data were reconstructed with our usual parameters used in clinical practice (OSEM-3D, 28 subsets, 8 iterations, no axial filtering, 3 mm transaxial post-reconstruction Gaussian filter) to generate a 20-min summed image, used as a reference (PET_STD). To simulate a 0.2 MBq/Kg injected activity, a second set of images (PET_ULD) was reconstructed over the first 2 min from list-mode data (corresponding exactly to 0.21 MBq/Kg taking into account radioactive decline). Reconstruction parameters of PET_ULD were optimized by physicists to ensure a high signal to noise ratio, for instance by increasing filtering (OSEM-3D, 32 subsets, 6 iterations, light axial filtering, 5 mm transaxial post-reconstruction Gaussian filter). The method to simulate low-dose datasets has been previously validated with experiments conducted with a Hoffman 3D brain phantom (BR/3D/P model, Data Spectrum Corporation) and has been extensively described in Soret et al.

We first evaluated the impact of an ultra-low-dose protocol on PET visual interpretation by evaluating intra-operator reproducibility. All PET volumes were reoriented along the bicommissural line. For visual interpretation, PET volumes were displayed in three orthogonal views with the French color scale. The minimal SUV value was set at 0 and the maximum was defined on midbrain uptake, for intensity normalization. Reading was done using an Advantage Workstation of GE Healthcare. Three raters with more than 10 years’ experience analyzed PET_STD and PET_ULD images independently, and classified 18F-FDG PET patterns into seven categories: normal (N), non-evaluable (NE), Alzheimer’s disease (AD), logopenic variant progressive primary aphasia (lvPPA), posterior cortical atrophy (PCA), semantic variant progressive primary aphasia (svPPA), or frontotemporal dementia (FTD). The reading sessions for PET_STD and PET_ULD were separated by more than 3 months. The available clinical information during reading sessions were only the age and sex of the patients, one or more suspected clinical diagnoses, or the prominent symptoms at presentation. We assessed the intra-operator agreement with Cohen’s kappa tests with 95% confidence intervals (CI), and the degree of agreement was characterized by kappa magnitude as defined by Landis and Koch. At the end of the two reading sessions, a consensus on the final imaging diagnosis was reached among the three raters, based on the PET_STD images.

We then extracted cortex-to-pons uptake ratios (SUVR) from PET_STD (SUVR_STD) and PET_ULD (SUVR_ULD) in 20 regions-of-interest with CortexID Suite software (v2.1, General Electric Healthcare), compared them with a paired Student’s T-test, and calculated the bias as ΔSUVR = |SUVR_STD – SUVR_ULD|. We assessed the reproducibility between SUVR measurements with a Bland–Altman graphical analysis. To evaluate the impact of the ultra-low-dose protocol according to the severity of 18F-FDG anomalies, we formed two sub-groups: (1) patients with "severe hypometabolism" as defined by PET_STD quantification revealing at least 3 hypometabolic regions with a Z-score ≤ -3 relative to the CortexID normal database; (2) patients with “normal to mildly decreased metabolism” comprising of the remaining patients.

Lastly, we assessed the impact of using PET_ULD rather than PET_STD on the results of between-group comparisons (AD versus FTD patients) using a VOI analysis as previously described.
**Results**

Based on the consensus reading between the three readers, PET\textsubscript{STD} was visually normal in 16 patients and suggestive of AD in 15, svPPA in 6, FTD in 8 and lvPPA or PCA in 5 (Table 1). Based on PET\textsubscript{STD} quantitative analysis, 20 patients were classified in the category “severe hypometabolism”. Thirty patients were classified as having “normal PET or moderate hypometabolism” (Table 1).

Figure 1 shows transverse slices of two patients suspected of AD obtained with standard and ultra-low dose protocol. The transverse slices are extracted from the Advantage Workstation (AW server 3.2, GE Healthcare) used to carry out the interpretation.

| Metabolic pattern                              | AD | lvPPA | PCA | svPPA | FTD | N | NE | All |
|-----------------------------------------------|----|-------|-----|-------|-----|---|----|-----|
| With severe hypometabolism (66.0 ± 5.7 year, 12 males) | 7  | 2     | 2   | 2     | 7   | 0 | 0  | 20  |
| With normal/moderate hypometabolism (68.4 ± 7.2 year, 14 males) | 8  | 1     | 0   | 4     | 1   | 16| 0  | 30  |
| All patients (67.4 ± 7.2 year, 26 males)        | 15 | 3     | 2   | 6     | 8   | 16| 0  | 50  |

Table 1. Number of patients classified for each metabolic pattern according to consensus based on PET\textsubscript{STD}; patients were also classified in two categories “severe hypometabolism” and “normal/moderate hypometabolism” according to regional PET\textsubscript{STD} quantification. N Normal, NE non-evaluable, AD Alzheimer’s disease, lvPPA logogenic variant of progressive primary aphasia, PCA posterior cortical atrophy, svPPA semantic variant of progressive primary aphasia, FTD frontotemporal dementia.
The amplitude of bias was similar in patients with normal metabolism/moderate hypometabolism and those with severe anomalies, i.e. 0.09 ± 0.062 and 0.08 ± 0.046, respectively (Table 3). Between-group comparisons (15 AD vs. 8 FTD) performed successively with PET\textsubscript{STD} and PET\textsubscript{ULD} generated very similar results (Fig. 3). As expected, SUVR\textsubscript{STD} were significantly decreased in AD compared with FTD in all patients (n = 50, 67.4 ± 7.2 year, 26 males) with 95% limits of agreement [−0.08; −0.24], Fig. 2) with the greatest differences involving the right (12.1%) and left (11.5%) posterior cingulate.

### Table 2. Intra-operator concordance between PET\textsubscript{STD} and PET\textsubscript{ULD} visual analyses. Cohen’s kappa value and 95% confidence interval characterized by (lower limit-upper limit) are shown. An intra-operator concordance of 1 means that the classification into 7 categories (N, NE, AD, lvPPA, PCA, svPPA, FTD) is the same when the reader visually interprets PET\textsubscript{STD} and PET\textsubscript{ULD}. Landis and Koch arbitrary characterized kappa values 0–0.20 as slight agreement, 0.21–0.40 as fair, 0.41–0.60 as moderate, 0.61–0.80 as substantial, and 0.81–1 as almost perfect agreement.

| Patient groups | Reader #1 | Reader #2 | Reader #3 |
|----------------|-----------|-----------|-----------|
| With severe hypometabolism (n = 20, age 66.0±5.7 year, 12 males) | 1.00 (1.0–1.0) | 0.96 (0.86–0.96) | 0.86 (0.80–0.91) |
| With normal/moderate hypometabolism (n = 30, 68.4±7.6 year, 14 males) | 0.85 (0.68–1.0) | 0.93 (0.75–1.1) | 0.92 (0.78–1.0) |
| All patients (n = 50, 67.4±7.2 year, 26 males) | 0.95 (0.87–1) | 0.76 (0.61–0.90) | 0.71 (0.55–0.86) |

### Table 3. Regional SUVR\textsubscript{ULD}, SUVR\textsubscript{STD} and difference ΔSUVR\% = (SUVR\textsubscript{STD} – SUVR\textsubscript{ULD})/SUVR\textsubscript{STD} expressed as mean ± standard deviation. *Indicates statistically significant difference between SUVR\textsubscript{STD} and SUVR\textsubscript{ULD} with p < 0.05. Ant. anterior, Post. posterior, Sup. superior, Inf. inferior.

| Patient groups | Patients with severe hypometabolism | Patients with normal/moderate hypometabolism | All patients |
|----------------|------------------------------------|------------------------------------------|-------------|
|                | SUVR\textsubscript{STD} | SUVR\textsubscript{ULD} | ΔSUVR\% | SUVR\textsubscript{STD} | SUVR\textsubscript{ULD} | ΔSUVR\% | SUVR\textsubscript{STD} | SUVR\textsubscript{ULD} | ΔSUVR\% |
| Left ant. cingulate | 1.12 | 1.03 | 8.5* | 1.21 | 1.13 | 6.2* | 1.17 | 1.08 | 7.1* |
| Right ant. cingulate | 1.07 | 0.99 | 7.6* | 1.20 | 1.13 | 6.5* | 1.15 | 1.07 | 6.9* |
| Left occipital lateral | 1.30 | 1.20 | 7.8* | 1.59 | 1.46 | 8.5* | 1.48 | 1.36 | 8.3* |
| Right occipital lateral | 1.28 | 1.19 | 7.0* | 1.60 | 1.49 | 6.9* | 1.47 | 1.37 | 7.3* |
| Left parietal inf | 1.15 | 1.07 | 7.0* | 1.49 | 1.38 | 7.2* | 1.35 | 1.26 | 7.1* |
| Right parietal inf | 1.14 | 1.06 | 7.4* | 1.49 | 1.39 | 6.6* | 1.35 | 1.26 | 6.8* |
| Left parietal sup | 1.18 | 1.06 | 10.4* | 1.46 | 1.31 | 9.8* | 1.35 | 1.21 | 10.0* |
| Right parietal sup | 1.13 | 1.02 | 9.0* | 1.45 | 1.34 | 7.0* | 1.32 | 1.22 | 7.6* |
| Left post. cingulate | 1.24 | 1.10 | 11.7* | 1.66 | 1.47 | 11.4* | 1.50 | 1.32 | 11.5* |
| Right post. cingulate | 1.24 | 1.09 | 12.2* | 1.68 | 1.48 | 12.1* | 1.51 | 1.33 | 12.1* |
| Left precuneus | 1.25 | 1.11 | 11.3* | 1.62 | 1.44 | 11.0* | 1.47 | 1.31 | 11.1* |
| Right precuneus | 1.22 | 1.11 | 9.0* | 1.61 | 1.47 | 8.8* | 1.46 | 1.33 | 8.8* |
| Left prefrontal lateral | 1.31 | 1.20 | 8.8* | 1.52 | 1.41 | 7.4* | 1.43 | 1.32 | 7.9* |
| Right prefrontal lateral | 1.27 | 1.18 | 6.7* | 1.50 | 1.43 | 4.9* | 1.41 | 1.33 | 5.6* |
| Left prefrontal medial | 1.24 | 1.14 | 8.1* | 1.38 | 1.30 | 6.1* | 1.32 | 1.23 | 6.8* |
| Right prefrontal medial | 1.18 | 1.11 | 6.0* | 1.35 | 1.28 | 5.1* | 1.28 | 1.21 | 5.4* |
| Left temporal lateral | 1.11 | 1.07 | 3.4* | 1.29 | 1.26 | 2.7* | 1.21 | 1.18 | 2.9* |
| Right temporal lateral | 1.06 | 1.04 | 2.2* | 1.31 | 1.28 | 1.6* | 1.21 | 1.19 | 1.8 |
| Left temporal mesial | 0.95 | 0.96 | −1.1 | 1.00 | 1.01 | −1.7* | 0.98 | 0.99 | −1.4 |
| Right temporal mesial | 0.93 | 0.92 | 1.0 | 1.02 | 1.03 | −0.7 | 0.99 | 0.99 | −0.1 |
| All | 1.16 ± 0.21 | 1.08 ± 0.17 | 6.8 ± 3.7* | 1.40 ± 0.29 | 1.31 ± 0.24 | 6.1 ± 3.8* | 1.31 ± 0.29 | 1.22 ± 0.25 | 6.4 ± 3.8* |
the parietal, precuneus, and lateral occipital cortices \( p < 0.005 \). VOI analysis performed with SUVRULD provided similar statistically significant results.

**Discussion**

We show that performing a 20-min brain PET/MRI with a 18F-FDG activity reduced to as low as 0.2 MBq/Kg is feasible without compromising quantitative measurements. It does not change either imaging diagnosis in patients with clear regional anomalies. However, it might influence readers’ final diagnosis in equivocal profiles with sparse, mild to moderate anomalies. Our finding suggest that the ultra-low-dose protocol could be an alternative for the differential diagnosis or follow-up in patients with severe cognitive impairment or dementia. Injecting 1–2 MBq/Kg 18F-FDG should be preferred for the early diagnosis of neurodegenerative disorders to guarantee a high image quality and better diagnostic performances.

**Figure 2.** Bland–Altman plot of regional differences SUVRSTD - SUVRULD as a function of \((SUVRSTD + SUVRULD)/2\) from all 20 VOIs for patients with normal/moderate hypometabolism (×) and patients with severe hypometabolism (·).

**Figure 3.** Mean and range SUVR for PETULD and PETSTD measured for all VOIs for patients considered as AD (15 patients) and FTD (8 patients).
In a previous study involving 100 brain 18F-FDG PET/MRI examinations, we found that the injected activity of 18F-FDG could be reduced from 2 to 1 MBq/Kg without modifying diagnostic performances and quantitative assessments in patients with cognitive impairment. In the present study, we tested a ten-fold activity reduction compared to the recommended activity (i.e. 0.2 vs. 2 MBq/Kg) resulting in a mean SUVR bias smaller than 7% over the whole cortex. The mean SUVR bias was greatest in the right posterior cingulate region (12.1%). The amplitude of bias was similar for patients with high or mild brain hypometabolism. Between-group comparisons based on SUVR<sub>2.0</sub> and SUVR<sub>0.67</sub> similarly differentiated AD from FTD. However, the visual analysis was substantially impacted in the patient sub-group with mild metabolism change. In this sub-group, experts reconsidered the final imaging-based diagnosis when switching from the standard to the ultra-low-dose PET images in 33% of cases, probably due to uncertainty related to lower image quality. As expected, the diagnosis was reconsidered less frequently (only 8% of cases) in the group with severe hypometabolic patterns.

Our findings are consistent with those of Fällmar et al. who reported a minimal impact of a four-fold decrease in injected activity on SUV measurements and diagnostic information analyzed with Z-score maps in 17 brain 18F-FDG PET/CT studies (neurodegenerative disorders vs controls). Our results involving 50 subjects suggest that an even greater dose reduction may be achievable for the purpose of quantitative measurements, probably because of the greater detector sensitivity of our PET/MRI camera.

Another recent study by Schiller et al. concerned dose reduction for brain 18F-FDG PET/CT in 25 patients diagnosed with AD or FTD. The authors performed VOI-based as well as voxel-based analyses, along with single-subject visual readings. All their analyses revealed the potential to divide by 4 the injected activity (from 200 to 50 MBq) without compromising diagnostic quality. In the VOI-based analysis, despite a decreased injected activity from 200 MBq down to 20 MBq, significant differences in mean normalized uptake between AD and FTD patients remained in the posterior cingulate, precuneus, temporal and parietal cortical VOIs. Our findings are in line with these results, showing that with 18F-FDG PET/MR, AD and FTD metabolic patterns can still be distinguished by VOI-based analysis even after a ten-fold decrease in injected activity. Schiller et al. also highlighted that concerning single-subject visual readings, a four-fold activity reduction is the limit in order to maintain optimal diagnostic performances in discriminating between AD and FTD. However, the ability to visually detect mild pathological changes was not evaluated. Our results showed substantial agreement between standard and ultra-low-dose protocols in patients with severe hypometabolism (kappa > 0.79). However, the ultra-low-dose protocol reached its limit in patients with mild metabolic changes. As previously published, a low dose (and not ultra-low dose) protocol (1 MBq/Kg) should be preferred for visually detecting mild metabolic changes.

In our study, we simulated the activity reduction by decreasing the PET duration, assuming that counting statistics would be decreased by the same factor. An alternative would have been to simulate a dose reduction by randomized subsampling of PET list-mode data. However, our approach was previously validated for our statistics would be decreased by the same factor. An alternative would have been to simulate a dose reduction by randomized subsampling of PET list-mode data. However, our approach was previously validated for our clinical brain FDG PET protocol with brain phantom measurements. To ensure that the comparison between 20 and 2-min PET would not be biased by metabolic changes over time, all images were strictly acquired at the final imaging-based diagnosis when switching from the standard to the ultra-low-dose PET images in 33% of cases, probably due to uncertainty related to lower image quality. As expected, the diagnosis was reconsidered less frequently (only 8% of cases) in the group with severe hypometabolic patterns.

Conclusion
Our simulation of an ultra-low dose protocol involving a 90% reduction of 18F-FDG injected activity did not significantly modify quantitative measurements of brain PET/MR images, suggesting that an activity as low as 0.2 MBq/Kg may be sufficient for reliable measurements of regional SUV ratios, and to differentiate AD from FTD. For visual interpretation, a substantial agreement was found between the standard (2 MBq/Kg) and ultra-low dose (0.2 MBq/Kg) protocols for patients with severe hypometabolism. The use of ultra-low doses would be of interest for younger patients, who may undergo repeated brain FDG-PET, for the diagnosis and monitoring encephalitis or psychiatric diseases, for example. It should be mentioned that reducing injected dose is of interest to improve the radiation protection of the PET technologists also. Reducing the injected dose also significantly reduces radiopharmaceutical costs in a department performing a lot of FDG-PET scans. However, for the early diagnosis of neurodegenerative disorders or when mild metabolism changes are expected, injecting 1–2 MBq/Kg should be preferred to guarantee a precise diagnosis. The ultra-low-dose protocol offers a possibility of substantial reduction in ionizing radiation exposure, but should be reserved for the differential diagnosis or follow-up in patients with severe cognitive impairment or dementia.

Data availability
The data that support the findings of this study are available from Pitie-Salpetriere Hospital but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Pitie-Salpetriere Hospital.

Received: 3 December 2021; Accepted: 3 August 2022
Published online: 12 September 2022
References

1. Oehmigen, M. et al. Radiotracer dose reduction in integrated PET/MR: Implications from national electrical manufacturers association phantom studies. *J. Nucl. Med.* 55, 1361–1367 (2014).

2. Soret, M. et al. Dose reduction in brain [18F]FDG PET/MRI: Give it half a chance. *Mol. Imaging Biol.* 22, 695–702 (2020).

3. Chen, K. T. et al. Generalization of deep learning models for ultra-low-count amyloid PET/MRI using transfer learning. *Eur. J. Nucl. Med. Mol. Imaging.* 47(13), 2998–3007 (2020).

4. Zhao, K. et al. Study of low-dose PET image recovery using supervised learning with CycleGAN. *PLoS ONE* 15(9), e0238455. https://doi.org/10.1371/journal.pone.0238455 (2020).

5. Guedi, E. et al. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. *Eur. J. Nucl. Med. Mol. Imaging.* 49, 632–651 (2022).

6. Landis, J. R. & Koch, G. G. The measurement of observer agreement for categorical data. *Biometrics* 33(1), 159–174 (1977).

7. Fallmar, D. et al. Validation of true low-dose 18F-FDG PET of the brain. *Am. J. Nucl. Med. Mol. Imaging.* 6, 269–276 (2016).

8. Fallmar, D. et al. Z-score maps from low-dose 18F-FDG PET of the brain in neurodegenerative dementia. *Am. J. Nucl. Med. Mol. Imaging.* 8, 239–246 (2018).

9. Schiller, F., Frings, L., Thurow, J., Meyer, P. T. & Mix, M. Limits for reduction of acquisition time and administered activity in 18F-FDG PET studies of alzheimer dementia and frontotemporal dementia. *J. Nucl. Med.* 60(12), 1764–1770 (2019).

10. Schaefferkoetter, J. et al. Low dose positron emission tomography emulation from decimated high statistics: A clinical validation study. *Med. Phys.* 46(6), 2638–2645. https://doi.org/10.1002/mp.13517 (2019).

Author contributions

A.B. and L.R. selected the patients. J.A.M. and M.S. reconstructed the data. S.D., M.O.H. and A.K. interpreted the clinical data. M.S., M.O.H., J.A.M., S.B., V.C.L. and A.K. contributed in writing the manuscript. All authors red and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to M.S.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022